Truncated RAF kinases drive resistance to MET inhibition in MET-addicted cancer cells.

// Consalvo Petti 1 , Gabriele Picco 1,2 , Maria Luisa Martelli 1 , Elena Trisolini 2,3 , Enrico Bucci 4 , Timothy Perera 5 , Claudio Isella 1,2 and Enzo Medico 1,2 1 Candiolo Cancer Institute - FPO IRCCS, Italy 2 Department of Oncology, University of Torino, Italy 3 Istituto Nazionale Biostrutture e Biosistemi, Roma, Italy 4 Biodigitalvalley Srl, Pont Saint Martin, Aosta, Italy 5 Janssen Research and Development, Oncology Discovery, Beerse, Belgium Correspondence: Enzo Medico, email: // Keywords : drug resistance; RAF1; BRAF; MET; gastric cancer Received : October 12, 2014 Accepted : November 14, 2014 Published : November 15, 2014 Abstract Constitutively active receptor tyrosine kinases (RTKs) are known oncogenic drivers and provide valuable therapeutic targets in many cancer types. However, clinical efficacy of RTK inhibitors is limited by intrinsic and acquired resistance. To identify genes conferring resistance to inhibition of the MET RTK, we conducted a forward genetics screen in the GTL-16 gastric cancer cell line, carrying MET amplification and exquisitely sensitive to MET inhibition. Cells were transduced with three different retroviral cDNA expression libraries and selected for growth in the presence of the MET inhibitor PHA-665752. Selected cells displayed robust and reproducible enrichment of library-derived cDNAs encoding truncated forms of RAF1 and BRAF proteins, whose silencing reversed the resistant phenotype. Transduction of naive GTL-16 cells with truncated, but not full length, RAF1 and BRAF conferred in vitro and in vivo resistance to MET inhibitors, which could be reversed by MEK inhibition. Induction of resistance by truncated RAFs was confirmed in other MET-addicted cell lines, and further extended to EGFR-addicted cells. These data show that truncated RAF1 and BRAF proteins, recently described as products of genomic rearrangements in gastric cancer and other malignancies, have the ability to render neoplastic cells resistant to RTK-targeted therapy.